Drug Profile
NP 2
Alternative Names: NET-ENK; NP2; NP2 Enkephalin; NTDDS expressing enkephalin; PGN-202Latest Information Update: 12 Apr 2017
Price :
$50
*
At a glance
- Originator Diamyd Medical
- Developer Periphagen Holdings
- Class Analgesics; Gene therapies
- Mechanism of Action Enkephalin modulators; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer pain; Neuropathic pain
Most Recent Events
- 12 Apr 2017 Discontinued - Phase-II for Cancer pain in USA (Intradermal) (Periphagen Holdings pipeline, April 2017)
- 12 Apr 2017 Discontinued - Preclinical for Neuropathic pain USA (Intradermal) (Periphagen Holdings pipeline, April 2017)
- 01 Nov 2013 Diamyd completes a phase II trial in Cancer pain in USA (NCT01291901)